News Release

Yamanouchi Pharmaceutical Co., Ltd.

YAMANOUCHI SHAKLEE PHARMA AND GLAXO WELLCOME SIGN
DEVELOPMENT AGREEMENT

May 21, 1998

Palo Alto, CA, (May 21, 1998)---Yamanouchi Shaklee Pharma announced today that it has entered into a Feasibility and Option agreement with Glaxo Group Limited, part of the Glaxo Wellcome Group, to enable the development and commercialization of prescription products for migraine therapy utilizing its WOWTAB(R) quick-dissolving, without-water tablet technology.

Glaxo Wellcome compounds targeted for commercialization as a WOWTAB(R) dosage form include the currently marketed compounds, as well as investigational compounds that have potential as future therapies for migraine. Unlike some rapidly dissolving formulations, the WOWTAB(R) technology produces a more durable tablet for patient convenience.

"The development and licensing of proprietary drug delivery technologies has become a key element of Yamanouchi Shaklee Pharma's business strategy," said Dan Green, Vice President of Business Development. "This agreement with Glaxo Wellcome, the market leader in prescription migraine therapy, marks another significant addition to our portfolio of drug delivery programs." The company is actively marketing WOWTAB(R), the first patented quick-dissolving technology designed for conventional manufacturing and packaging equipment, plus the OCASTM (Oral Controlled Absorption System) controlled-release technology, and has additional technologies in its development pipeline.

Yamanouchi Shaklee Pharma, located in the Stanford Research Park in Palo Alto, California, is a division of San Francisco-based Shaklee Corporation. Shaklee Corporation became a wholly owned subsidiary of Yamanouchi Pharmaceutical Co., Ltd. in 1989. With operations worldwide, Yamanouchi ranks third in sales in the Japanese pharmaceutical market.